Next Generation of Ozempic: 3 Major Breakthroughs to Watch

Semaglutide drugs are having their moment. In just seven years, GLP-1 medications like Ozempic surpassed insulin as the second most common treatment for type 2 diabetes. But the competition hasn't slowed down. What’s next for scientists working on obesity drugs? While eliminating side effects is an obvious goal, the real race is even more captivating.

The Battle to Save Your Muscles

A stark reality faces current users: 40% of weight loss comes from muscle mass, not fat. Muscle is key for metabolism, physical function, and overall health. Less muscle often leads to rapid weight return after stopping medication.

Eli Lilly spent $1.9bn to acquire biopharmaceutical company for its muscle-protection treatments. Regeneron has enlisted hundreds of volunteers to test two muscle-boosting antibodies and is preparing to start recruiting obese patients for the trial soon. BioAgea is actively testing Azelaprag, a muscle-regeneration drug, and reports promising results. Meanwhile, Swiss drugmaker Roche Holding plans to blend muscular dystrophy treatment with weight loss medicine